Skip to main content
. Author manuscript; available in PMC: 2013 Sep 16.
Published in final edited form as: J Am Coll Nutr. 2007 Apr;26(2):95–102. doi: 10.1080/07315724.2007.10719590

Figure 2.

Figure 2

Upper Panel: Changes in brachial artery flow-mediated dilation (FMD) compared to pre-treatment are displayed for Placebo and EGCG. FMD improved two hours after a single 300 mg dose of EGCG (*P=0.01), while FMD was not changed after two weeks of EGCG 150 mg twice daily (P=0.12). Placebo had no effect at the two-hour and two-week time points. Lower Panel: Changes in plasma EGCG concentration compared to pre-treatment concentration are displayed for Placebo and EGCG (n=38). Plasma ECGC concentrations were increased two hours after a single 300 mg dose of EGCG (P<0.001), while trough plasma EGCG concentrations (approximately 14 hours after the last dose) were unchanged after two weeks of EGCG 150 mg twice daily. Data are mean ± SEM.